BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $8
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $5
Buy Rating on Humacyte: Long-Term Growth Potential and Symvess Launch Optimism
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $17
Humacyte Price Target Maintained With a $25.00/Share by D. Boral Capital
Humacyte Is Maintained at Buy by D. Boral Capital
Humacyte Analyst Ratings
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $8
BTIG Adjusts Price Target on Humacyte to $8 From $10, Maintains Buy Rating
Humacyte Is Maintained at Buy by D. Boral Capital
Humacyte Price Target Maintained With a $25.00/Share by D. Boral Capital
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $5
D. Boral Capital Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Innovative Eyewear, Inc. (LUCY)
Humacyte Analyst Ratings
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $7.5
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $7.5
Humacyte's SYMVESS Launch and Strategic Positioning Drive Buy Rating
Humacyte Price Target Maintained With a $25.00/Share by D. Boral Capital